Edge Therapeutics Inc. received a notice of noncompliance from Nasdaq for failing to meet the stock exchange's minimum $1 bid price listing standard.

The exchange granted Edge Therapeutics 180 calendar days, or until March 4, 2019, to regain compliance with the rule.

The Berkeley Heights, N.J.-based biotechnology said the notice has no immediate effect on its common stock which trades under the EDGE symbol on the Nasdaq Global Select Market.